SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after a significant drop following mixed Phase 3 trial results, specifically related to high placebo response impacting statistical significance. The conversation centers on whether the sell-off is an overreaction given the company's cash reserves and ongoing pipeline, with some speculating about a potential buyout and others wary of the mixed data. Community members are actively discussing dip-buying strategies, potential bounce-back scenarios, and comparisons to competitor performance.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Shares of Robinhood are trending as the stock rallies to new all-time highs, fueled by optimism around its S&P 500 inclusion and growth in its prediction markets business; the community is closely watching for continued momentum. Several analysts have recently raised their price targets, with some traders speculating on further upside. The stock has become a favorite among millennial traders as it rides the crypto wave and wealth transfer megatrend.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to a sharp drop in stock price following remarks made by a former FDA official, George Tidmarsh, regarding the drug Voclosporin. The community is expressing concerns about the validity and timing of the statement, with some suspecting market manipulation and questioning the company's leadership response. The drop has also impacted buyout hopes.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending following news of a partnership with Google to enhance AI-powered shopping experiences. While some investors are excited about the potential growth, others express frustration with the stock's historical underperformance and question whether the partnership will provide an immediate catalyst. Community members are debating whether this is a turning point or another false start for the fintech giant.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to a video posted by Trump discussing the medical benefits of CBD for seniors, sparking community discussion around potential rescheduling.  Traders are actively weighing the implications of potential policy changes and the sector's volatile nature, while some highlight positive movement in European cannabis markets. The community speculates on the timing and impact of any official announcements.

Boqii Holding Ltd. operates as a holding company with interest in operating online pet stores. It provides services through its subsidiaries. The company was founded by Liang Hao, Tang Yingzhi, and Chen Di in December 2007 and is headquartered in Shanghai, China.

Boqii Holding Limited - Ordinary Shares - Class A

Boqii Holding Limited - ADR

Boqii Holding is trending due to speculation around a potential gamma squeeze and significant price movement, leading to community discussions about float size and potential price targets. Some traders are pointing to technical indicators and chart patterns, while others caution about the risks associated with Chinese stocks and potential pump-and-dump schemes. The stock's volatility and history of reverse splits are also prominent points of discussion among investors.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending following a strong earnings report, with revenue and GMV growth exceeding expectations. The community is discussing the company's resilience in the face of potential headwinds like tariffs, along with its expanding partnerships and AI initiatives. Bullish sentiment is fueled by raised price targets and the anticipation of continued growth, though some caution against overvaluation.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt Holdings is trending due to renewed interest following news of a new board appointment, sparking discussions about the company's potential growth strategy within the digital asset space. The community is actively speculating about the impact of new leadership and potential partnerships, especially regarding expansion into foreign markets and web3 technologies. Bullish sentiment is building around the possibility of a short squeeze and the company's strengthened financial position after debt reduction.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending amidst a short report from Fuzzy Panda Research, alleging inflated ARR and questionable partnerships, which the company has refuted. The community is fiercely debating the report's validity, with some viewing it as a buying opportunity ahead of earnings and others expressing concern. Bulls emphasize institutional investment and potential for high growth in the AI-powered commerce sector, while bears point to past financial performance and management's track record.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals (ENTA) is trending due to mixed Phase 2b study results for its RSV treatment, zelicapavir, causing investor debate and a stock sell-off. While the primary endpoint was missed, secondary endpoints were met, fueling discussions about the drug's potential and Phase 3 progression, particularly regarding FDA priorities. Community talking points include potential short squeezes given the high short interest and oversold RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors need to pay close attention to AUPH stock based on the movements in the options market lately.

Retail chatter around Aurinia Pharmaceuticals picked up pace late Sunday, with investors eyeing an update on the company’s early-stage AUR200 trial targeting autoimmune conditions later in the day.The experimental therapy, first dosed in healthy volunteers in September 2024, is being evaluated in a single ascending dose study.&nbsp;The program is assessing safety, tolerability, drug behavior in the body, and biomarker response.&nbsp;AUR200 works by targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), proteins involved in immune system regulation.&nbsp;The company has said it plans to pursue one broader indication and one rare disease, both with relatively few existing treatments.&nbsp;Funding for development is coming from Aurinia’s current cash flow.In May,&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia</a> reported new findings from its Phase 3 AURORA 1 study of Lupkynis (voclosporin), its approved treatment for lupus nephritis.&nbsp;The post-hoc analysis suggested&nbsp;that patients receiving triple therapy with Lupkynis, mycophenolate mofetil (MMF), and low-dose steroids achieved better proteinuria outcomes than those on MMF and steroids alone.&nbsp;&nbsp;Adverse event rates were comparable between groups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they wouldn’t be selling even if the stock hit $10, saying they were “in it for the big bucks.”&nbsp;<stembedurl>https://stocktwits.com/RedBarnCannabis/message/619401660</stembedurl>Another pointed out that historically, strong data has moved the stock significantly and stated that with Aurinia’s sizable cash reserves, dilution concerns were minimal, adding that they were hoping for double-digit gains following the update.<stembedurl>https://stocktwits.com/timfris/message/619390483</stembedurl>The stock has declined 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Equity

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Company News for May 13, 2025

Shares of Aurinia Pharmaceuticals Inc. (AUPH) surged 3% in premarket trading on Monday after the company’s first-quarter (Q1) earnings topped Wall Street expectations.The biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025">reported</a> a 24% year-on-year (YoY) jump in its first-quarter (Q1) total revenue to $62.5 million, surpassing an analyst estimate of $61.06 million, according to Finchat data.The surge in revenue was primarily driven by a 25% YoY jump in net product sales of Lupkynis, the company’s FDA-approved oral therapy for treating adult patients with active lupus nephritis, to $60 million.For the three months ending March 31, 2025, the company reported a net income of $23.3 million, compared to a loss of $10.7 million in 2024.Diluted earnings per share came in at $0.16 for the quarter, compared to a loss of $0.07 per share recorded in the corresponding period of 2024, and above an analyst estimate of $0.1. &nbsp;&nbsp;&nbsp;&nbsp;Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments of $312.9 million, compared to $358.5 million on Dec. 31, 2024.CEO Peter Greenleaf said the company looks forward to a “strong performance” in 2025.The firm also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.On Stocktwits, retail sentiment around Aurinia jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:632/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_12_at_7_28_54_AM_png_b95ef3aeed.webp" alt="AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits" width="632" height="60"><figcaption>AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down by about 9% this year but up by over 59% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/expedia-retail-traders-remain-optimistic-despite-q1-revenue-miss/chiNeqjRbme">Expedia Retail Traders Remain Optimistic Despite Q1 Revenue Miss Ahead Of Holiday Travel Season</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Biotech stocks are a hot-button topic for retail investors on Stocktwits, where over&nbsp;four million users track these companies, hoping to spot the next big therapeutic breakthrough.Two names currently trending in the space are Mainz Biomed, a molecular genetics cancer diagnostic company based in Germany, and Aurinia Pharmaceuticals Inc., a Canadian biopharmaceutical firm focused on autoimmune disease treatments.Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.&nbsp;However, Aurinia maintains nearly three times the following of Mainz on the platform.&nbsp;A recent Stocktwits poll of over 1,100 respondents found that 53% believe Mainz offers more upside, compared to 34% favoring Aurinia.<figure class="image"><img style="aspect-ratio:1294/736;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MYNZ_vs_AUPH_poll_as_of_March_6_43ea585c2e.png" alt="MYNZ vs AUPH poll as of March 6.png" width="1294" height="736"><figcaption>MYNZ vs AUPH poll as of March 6. | source: Stocktwits</figcaption></figure>Maxim Group recently initiated coverage on Mainz with a ‘Buy’ rating and a $14 price target, highlighting its role in the $4 billion colorectal cancer screening market.&nbsp;The firm is optimistic about Mainz’s next-generation test, which uses mRNA biomarkers to improve the detection of pre-cancerous adenomas and potentially enhance colorectal cancer prevention.&nbsp;Mainz is conducting a clinical study on this test, with data expected in the second half of 2025, and plans to finalize protocols for a pivotal U.S. study in 2026.In October, Mainz reported fiscal first-half loss per share had narrowed to $0.48 from $1 a year earlier, with revenue rising to $520,773 from $499,049.&nbsp;The company’s cash and cash equivalents stood at $977,764.Retail traders on Stocktwits have pointed to increasing institutional investment in Mainz, with funds such as Artisan Mid Cap Fund reportedly raising their stakes.&nbsp;<stembedurl>https://stocktwits.com/CarterWood/message/607119518</stembedurl>Some traders speculate that Mainz could see significant catalysts, including an upcoming product launch, a potential partnership, accelerated clinical progress, or an FDA resubmission with fast-track approval.<stembedurl>https://stocktwits.com/FosterD_Nightfall/message/607091090</stembedurl>Aurinia, in contrast, has gained attention for its development of AUR200, a therapy targeting BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The company believes this could become a best-in-class treatment for autoimmune diseases.&nbsp;It has already commercialized Lupkynis, the first FDA-approved oral therapy for adult patients with active lupus nephritis.In its latest financial report, Aurinia posted fourth-quarter earnings of $0.01 per diluted share, a sharp turnaround from a $0.19 loss a year earlier and better than analysts’ projected $0.02 per-share loss.&nbsp;Revenue for the quarter rose to $59.9 million from $45.1 million a year earlier but fell slightly below Wall Street estimates of $60.1 million.&nbsp;For 2025, Aurinia forecasts revenue between $250 million and $260 million, trailing the $274.4 million expected by analysts.Last year, Aurinia said it would <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-surges-on-insider-buying/cJa2dg8Rin">strengthen</a> its financial position by cutting nearly half its staff to save over $40 million annually.&nbsp;The company also made leadership changes, including CEO Peter Greenleaf’s conditional resignation as a director.&nbsp;As of Dec. 31, 2024, Aurinia held cash, cash equivalents, and investments totaling $358.5 million, up slightly from $350.7 million a year earlier.According to Koyfin data, short interest in Aurinia stood at 7%, compared to 5.1% for Mainz.&nbsp;Over the past year, Aurinia shares have gained more than 44%, though they are down over 9% year-to-date.&nbsp;Mainz, meanwhile, has fallen more than 86% in the past 12 months but has rebounded over 25% since the start of this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet

Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%. 

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on...

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AUPH News

AUPH Aurinia Pharmaceuticals Inc